Barclays Maintains Exscientia(EXAI.US) With Buy Rating, Maintains Target Price $10

Barclays analyst Peter Lawson maintains $Exscientia(EXAI.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of 44.1% and a total a

moomoo NewsMay 23 06:32 ET

Barclays Keeps Their Buy Rating on Exscientia Plc (EXAI)

TipRanksMay 22 04:06 ET

Sector Update: Health Care Stocks Edge Higher Tuesday Afternoon

Health care stocks were edging up Tuesday afternoon, with the NYSE Health Care Index rising 0.2% and the Health Care Select Sector SPDR Fund (XLV) fractionally higher. The iShares Biotechnology ETF (I

MT NewswiresMay 21 13:55 ET

Exscientia to Reduce Up to 25% Workforce by Year End

Exscientia (EXAI) said Tuesday that it expects to complete a headcount reduction of 20% to 25% by the end of 2024. The job cuts are part of cost efficiency measures that the company will initiate to s

MT NewswiresMay 21 12:15 ET

Express News | Exscientia Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Sales Results

BenzingaMay 21 11:38 ET

Tandem Diabetes Care, Guardion Health, GT Biopharma Among Healthcare Movers

Seeking AlphaMay 21 10:00 ET